PepVax, Inc.

Immunotherapy Revolutionized

  • Stage Product In Development
  • Industry Biotechnology
  • Location Bethesda, MD, USA
  • Currency USD
  • Founded February 2013
  • Employees 4
  • Incorporation Type C-corp
  • Website pepvax.co

Company Summary

PepVax, Inc. has developed a novel DNA-based drug delivery platform, called SMARTmid™, for the development of next-generation cell, gene, and immunotherapies, all manufactured inside the patient (Intusic™).

Team

  • President and CEO

    Biotechnology entrepreneur with extensive experience in the healthcare and life sciences industry. He has a Master's in Biotechnology from University of Pennsylvania with experience in business development, consulting for start-ups, as well as research in academia and pharmaceutical industry focusing on antibiotics and vaccines.

  • Anton Dormer
    Chairman and Chief Scientific Officer

    Biotechnology entrepreneur with extensive experience in the healthcare and life sciences industry. He has a Master's in Biotechnology from University of Pennsylvania with experience in business development, consulting for start-ups, as well as research in academia and pharmaceutical industry focusing on antibiotics and vaccines.

  • VP, Bioinformatics

    Dr. Daniel Achinko is a research scientist at the University of Yaounde I (UYI), Cameroon. He received his doctorate in Bioinformatics with a focus on Co-parasitic infections, and a Master's in Molecular Parasitology with focus on genotyping the Plasmodium strains of malaria. He is currently a member of the East African Bioinformatic group and the International Society of Computational Biology.

Advisors

  • Sherman Rogers
    Lawyer
    Unconfirmed
    Elton Norman
    Accountant
    Unconfirmed
    Patent Lawyer, Scientific Board Advisor
  • Scientific Advisory Board

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free